8H9 bispecific antibody - Y-mAbs Therapeutics

Drug Profile

8H9 bispecific antibody - Y-mAbs Therapeutics

Alternative Names: Hu8H9-BsAb (B7-H3xCD3)

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Y-mAbs Therapeutics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 09 Sep 2016 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 16 Jun 2016 Preclinical trials in Solid tumours in USA (unspecified route) (Y-mAbs Therapeutics pipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top